

CITATION REPORT

List of articles citing

Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism

DOI: 10.1111/j.1365-2125.1991.tb05630.x

British Journal of Clinical Pharmacology, 1991, 32, 136-7.

Source: <https://exaly.com/paper-pdf/21952138/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
74	P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. <i>Clinical Pharmacokinetics</i> , 1992 , 23, 132-46	6.2	130
73	Inhibitors of imipramine metabolism by human liver microsomes. <i>British Journal of Clinical Pharmacology</i> , 1992 , 34, 256-61	3.8	126
72	The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. <i>British Journal of Clinical Pharmacology</i> , 1992 , 34, 262-5	3.8	348
71	The pharmacogenetics of the selective serotonin reuptake inhibitors. <i>The Clinical Investigator</i> , 1993 , 71, 1002-9		59
70	Dextromethorphan O-demethylation polymorphism in Jordanians. <i>European Journal of Clinical Pharmacology</i> , 1993 , 45, 271-3	2.8	8
69	Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. <i>European Journal of Clinical Pharmacology</i> , 1993 , 44, 349-55	2.8	174
68	Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study. <i>European Journal of Clinical Pharmacology</i> , 1993 , 44, 403-5	2.8	29
67	Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. <i>Psychopharmacology</i> , 1993 , 110, 302-8	4.7	60
66	Clinical pharmacokinetics of selective serotonin reuptake inhibitors. <i>Clinical Pharmacokinetics</i> , 1993 , 24, 203-20	6.2	222
65	Risk factors in elderly taking psychotropic drugs: Significance of genetic polymorphism in drug oxidation. <i>Nordic Journal of Psychiatry</i> , 1993 , 47, 85-89	2.3	4
64	Antidepressant therapy in the physically ill: a therapeutic opportunity for the selective 5-HT re-uptake inhibitors?. <i>Journal of Psychopharmacology</i> , 1993 , 7, 112-8	4.6	3
63	SSRIs and tricyclic antidepressants. <i>British Journal of Psychiatry</i> , 1993 , 162, 426	5.4	1
62	Pharmacogenetics of Agents Acting on the Central Nervous System. <i>Journal of Pharmacy Practice</i> , 1993 , 6, 2-16	1.3	2
61	Drug Interactions in Psychopharmacology. <i>Psychiatric Clinics of North America</i> , 1993 , 16, 647-671	3.1	18
60	The effects of desipramine and iprindole on levels of enantiomers of fluoxetine in rat brain and urine. <i>Chirality</i> , 1994 , 6, 86-90	2.1	9
59	Metabolism and chirality in psychopharmacology. <i>Biological Psychiatry</i> , 1994 , 36, 211-3	7.9	5
58	Fluoxetine. <i>New England Journal of Medicine</i> , 1994 , 331, 1354-61	59.2	169

57	Clinical pharmacokinetics of fluoxetine. <i>Clinical Pharmacokinetics</i> , 1994 , 26, 201-14	6.2	211
56	Pharmacokinetics of the newer antidepressants: clinical relevance. <i>American Journal of Medicine</i> , 1994 , 97, 13S-23S	2.4	70
55	Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. <i>British Journal of Clinical Pharmacology</i> , 1994 , 38, 23-31	3.8	129
54	The use of toxicokinetics for the safety assessment of drugs acting in the brain. <i>Molecular Neurobiology</i> , 1995 , 11, 193-216	6.2	10
53	Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses. <i>British Journal of Psychiatry</i> , 1995 , 167, 575-80	5.4	49
52	The SSRIs: advantages, disadvantages and differences. <i>Journal of Psychopharmacology</i> , 1995 , 9, 163-78	4.6	79
51	Are interspecies comparisons in the toxicity of centrally acting drugs valid without brain concentrations? A commentary. <i>Neurochemistry International</i> , 1995 , 26, 103-10	4.4	2
50	Protein kinase C in rat brain cortex and hippocampus: effect of repeated administration of fluoxetine and desipramine. <i>British Journal of Pharmacology</i> , 1995 , 115, 595-600	8.6	48
49	Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. <i>Biochemical Pharmacology</i> , 1995 , 50, 833-7	6	39
48	Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness. <i>Drugs and Aging</i> , 1995 , 6, 64-84	4.7	25
47	Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. <i>Clinical Pharmacokinetics</i> , 1995 , 29 Suppl 1, 45-52	6.2	56
46	Venlafaxine oxidation in vitro is catalysed by CYP2D6. <i>British Journal of Clinical Pharmacology</i> , 1996 , 41, 149-56	3.8	185
45	Clinically Significant Drug Interactions with General Anaesthetics. <i>CNS Drugs</i> , 1997 , 8, 51-78	6.7	8
44	Drugs Update Column: Metabolic interaction between fluoxetine and tricyclic antidepressants: benefit for the patient or potential problem?. <i>Journal of Substance Use</i> , 1997 , 2, 5-7		1
43	Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. <i>Clinical Pharmacokinetics</i> , 1997 , 33, 454-71	6.2	129
42	Interpatient variability: genetic predisposition and other genetic factors. <i>Journal of Clinical Pharmacology</i> , 1997 , 37, 635-48	2.9	18
41	Adverse drug reactions and debrisoquine/sparteine (P450IID6) polymorphism in patients with fibromyalgia. <i>Clinical Rheumatology</i> , 1997 , 16, 291-5	3.9	5
40	Determination of p-trifluoromethylphenol, a metabolite of fluoxetine, in tissues and body fluids using an electron-capture gas chromatographic procedure. <i>Biomedical Applications</i> , 1997 , 698, 103-9		15

39	Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome". <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 63, 403-13	6.1	19
38	In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. <i>Fundamental and Clinical Pharmacology</i> , 1998 , 12, 194-9	3.1	39
37	Clonidine: adverse responses. <i>Journal of Paediatrics and Child Health</i> , 1998 , 34, 501-2	1.3	3
36	Pharmacogenetics of the hepatic cytochrome P450 enzyme system: its relevance for prescribing in psychiatry. <i>Irish Journal of Psychological Medicine</i> , 1998 , 15, 96-99	3	
35	Effect of fluoxetine on pharmacokinetics of ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 1998 , 42, 3107-12	5.9	35
34	Pharmacokinetics of haloperidol: an update. <i>Clinical Pharmacokinetics</i> , 1999 , 37, 435-56	6.2	171
33	Pharmacokinetics of selective serotonin reuptake inhibitors. 2000 , 85, 11-28		568
32	Effect of venlafaxine on imipramine metabolism. <i>Psychiatry Research</i> , 2000 , 96, 235-43	9.9	33
31	Evidence for the catalysis of dextromethorphan O-demethylation by a CYP2D6-like enzyme in pig liver. <i>Toxicology in Vitro</i> , 2000 , 14, 253-63	3.6	20
30	Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. <i>European Neuropsychopharmacology</i> , 2001 , 11, 275-83	1.2	100
29	Serum concentrations of fluoxetine in the clinical treatment setting. <i>Therapeutic Drug Monitoring</i> , 2001 , 23, 139-47	3.2	48
28	CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. <i>Acta Psychiatrica Scandinavica</i> , 2001 , 104, 173-92	6.5	285
27	Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 419-23	1.7	80
26	Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2002 , 90, 144-9		25
25	Clinical pharmacokinetics of drugs used to treat urge incontinence. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 1243-85	6.2	91
24	Antidepressant drugs in the elderly--role of the cytochrome P450 2D6. <i>World Journal of Biological Psychiatry</i> , 2003 , 4, 74-80	3.8	10
23	Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. <i>Pharmacotherapy</i> , 2004 , 24, 482-7	5.8	4
22	NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2004 , 71, 193-280		21

21	The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006 , 256, 287-93	5.1	24
20	Cytochrome P450-catalyzed pathways in human brain: metabolism meets pharmacology or old drugs with new mechanism of action?. 2007 , 113, 537-45		37
19	5-Hydroxytryptamine ₂ and beta-adrenergic receptor regulation in rat brain following chronic treatment with desipramine and fluoxetine alone and in combination. <i>Journal of Neurochemistry</i> , 1994 , 62, 2262-8	6	59
18	Differential time- and NADPH-dependent inhibition of CYP2C19 by enantiomers of fluoxetine. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 695-8	4	15
17	Steady-state concentrations of mirtazapine, N-desmethyilmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 63-70	6.2	35
16	Kinetic interaction between fluoxetine and imipramine as a function of elevated serum alpha-1-acid glycoprotein levels. <i>Journal of Pharmacy and Pharmacology</i> , 1998 , 50, 419-24	4.8	2
15	Methadone: a review of drug-drug and pathophysiological interactions. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2011 , 48, 171-95	9.4	53
14	Role of genetic polymorphism in psychopharmacology--an update. <i>Psychopharmacology Series</i> , 1993 , 10, 199-211		15
13	Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 273-85	1.7	61
12	Lack of change in fluoxetine and norfluoxetine kinetics when switching from fluoxetine to paroxetine. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 320-3	1.7	2
11	Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 345-55	1.7	59
10	Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. <i>Journal of Clinical Psychopharmacology</i> , 1997 , 17, 113-7	1.7	58
9	Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes. <i>Journal of Clinical Psychopharmacology</i> , 2000 , 20, 428-34	1.7	25
8	Steady state concentrations of the enantiomers of mianserin and desmethyilmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine. <i>Therapeutic Drug Monitoring</i> , 1998 , 20, 7-13	3.2	21
7	Advances in understanding drug metabolism and its contribution to variability in patient response. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 110-3	3.2	32
6	Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 143-54	3.2	105
5	Interaction between cyclosporin and fluoxetine. <i>BMJ: British Medical Journal</i> , 1995 , 311, 422		16
4	Cytochrome P450 Reactions in the Human Brain. 2007 , 43-91		

3 Psychopharmakotherapie. **1996**, 421-454

2 Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping. *Journal of Psychiatry and Neuroscience*, **1994**, 19, 30-44

4-5 14

1 The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition. *Current Opinion in Drug Discovery & Development*, **2010**, 13, 66-77

23